search
Documents
Verification of proposed USP-NF Flurbiprofen sodium Assay and Organic Impurities Monograph and subsequent Modernization under Allowable Adjustments.
Flurbiprofen, a derivative of propionic acid, is known to function as a nonsteroidal anti-inflammatory agent (NSAIA) exhibiting both antipyretic and analgesic properties. Oral forms of flurbiprofen can be utilized for the symptomatic management of rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. In this technical note we demonstrate that both Luna™ Omega C18 (5 µm 250 x 4.6 mm) and Kinetex™ C18 (5 µm 250 x 4.6 mm) meet the acceptance criteria for the proposed USP flurbiprofen sodium assay and organic impurities tests. The USP Chapter specifies the use of an L1 column. Further, modernization of this method was verified on a Kinetex 2.6 µm C18 (150 x 3.0 mm) column. Method parameters were scaled in accordance with the allowable adjustments within USP 621 with respect to the flow-rate and gradient
Verification of proposed USP-NF Flurbiprofen sodium Assay and Organic Impurities Monograph and subsequent Modernization under Allowable Adjustments.
Flurbiprofen, a derivative of propionic acid, is known to function as a nonsteroidal anti-inflammatory agent (NSAIA) exhibiting both antipyretic and analgesic properties. Oral forms of flurbiprofen can be utilized for the symptomatic management of rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. In this technical note we demonstrate that both Luna™ Omega C18 (5 µm 250 x 4.6 mm) and Kinetex™ C18 (5 µm 250 x 4.6 mm) meet the acceptance criteria for the proposed USP flurbiprofen sodium assay and organic impurities tests. The USP Chapter specifies the use of an L1 column. Further, modernization of this method was verified on a Kinetex 2.6 µm C18 (150 x 3.0 mm) column. Method parameters were scaled in accordance with the allowable adjustments within USP 621 with respect to the flow-rate and gradient
Document Type:
Technical Notes
Target Industries:
Techniques:
Brands:
Phases:
Verification of proposed USP-NF Flurbiprofen sodium Assay and Organic Impurities Monograph and subsequent Modernization under Allowable Adjustments.
Flurbiprofen, a derivative of propionic acid, is known to function as a nonsteroidal anti-inflammatory agent (NSAIA) exhibiting both antipyretic and analgesic properties. Oral forms of flurbiprofen can be utilized for the symptomatic management of rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. In this technical note we demonstrate that both Luna™ Omega C18 (5 µm 250 x 4.6 mm) and Kinetex™ C18 (5 µm 250 x 4.6 mm) meet the acceptance criteria for the proposed USP flurbiprofen sodium assay and organic impurities tests. The USP Chapter specifies the use of an L1 column. Further, modernization of this method was verified on a Kinetex 2.6 µm C18 (150 x 3.0 mm) column. Method parameters were scaled in accordance with the allowable adjustments within USP 621 with respect to the flow-rate and gradient
| Target Industries: | Pharmaceutical |
| Techniques: | HPLC Reversed Phase |
| Brands: | Kinetex, Luna Omega |
| Phases: | Kinetex C18, Luna Omega C18 |
Phenomenex is a technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers worldwide.
Phenomenex is a technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers worldwide.